Rx00242 - Tranexamic Acid


Name:
Tranexamic Acid
Rx ID:
Rx00242
Validation Level:
Reference ID:
DB00302
Primary Indications:
Hemophilia; hemorrhage; tooth extraction
Orphan Indications:
Hereditary angioneurotic edema; prostatectomy; hemorrhage; fibrinolysis; fibrinogenolysis
Rare Indications:
Hemophilia; hemorrhage; tooth extraction
Common Indications:
Cyclic heavy menstrual bleeding
Drug Interactions:
No annotated drug interactions in DrugBank.
Food Interactions:
No annotated food interactions in DrugBank.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00242
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
hemorrhage fibrinogenolysis 55 2111 1307 80.433 2.11E-82 6.77e-79
tooth extraction hemorrhage 20 2755 2111 13.876 1.82E-16 5.84e-13
hemophilia hemorrhage 4 23 2111 332.414 1.31E-09 4.19e-06

Chemical, Pharmacological and Biological Annotations


ATC Code:
B02AA02
Brands:
Cyclo-F; Espercil; Femstrual; Rikavarin; Transamin; Transcam; Traxyl
Category:
Antifibrinolytic Agents
ChEBI ID:
48669
KEGG Drug ID:
D01136
SMILE:
NC[C@H]1CC[C@@H](CC1)C(O)=O
InChI:
1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-
Classification:
Kingdom:
Organic Compounds
Superclass:
Organonitrogen Compounds
Class:
Amines
Subclass:
Polyamines
Indication:
For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in mens...
Click to show more...
Pharmacodynamics:
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor...
Click to show more...
Description:
Antifibrinolytic hemostatic used in severe hemorrhage. [PubChem]
Mechanism:
Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma p...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Ready biodegradable
Rat acute toxicity:
1.0517 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org